Artio Medical, a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, announced today the closing of an additional $12 million tranche of Series A financing, bringing the total to $46 million. Led by existing investors Nathaniel and Sarah Hagedorn, the funding will be used to complete the company's first-in-human clinical study of its Amplifi™ Vein Dilation System and prepare for commercialization of its Solus Gold™ Embolization Device.

Artio Medical is a medical device company committed to developing innovative products for the treatment of peripheral vascular, neurovascular, and structural heart diseases. For more information, please visit www.artiomedical.com.